Oxford begins first human trial of Bundibugyo Ebola vaccine
Credit: CGTN
The Phase I study, designated BD-Ebov, will assess the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18 to 55 in Oxford.
Current Subscription | Free Limited Usage - UPGRADE NOW!
Avatar
Gallery Name
Password
Usage Counts
- Credits Balance: 0
- Lifetime Credits Awarded: 0
- Lifetime Uploads: 0
- AI Image Processing: 0
- AI Text-to-Speech (TTS): 0
- Generated Videos: 0
- Video Total Seconds: 0
- Storage Space: 0.0
